Evidence map›Paper›PMID 27515759›Full record

ArticleBMJ open2016

Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study.

Sveinung Wergeland Sørbye, Silje Fismen, Tore Jarl Gutteberg, Elin Synnøve Mortensen, Finn Egil Skjeldestad

Open access · goldAbstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 28 citations in OpenAlex.

  1. Observational
  2. Review
  3. Review of triage strategies for atypical squamous cells of undetermined significance among young women.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Sveinung Wergeland SørbyeDepartment of Clinical Pathology, University Hospital of North Norway, Tromsø, Norway.ORCID 0000-0002-8250-3992
Silje FismenDepartment of Clinical Pathology, University Hospital of North Norway, Tromsø, Norway.
Tore Jarl GuttebergDepartment of Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway Department of Medical Biology, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway.
Elin Synnøve MortensenDepartment of Clinical Pathology, University Hospital of North Norway, Tromsø, Norway Department of Medical Biology, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway.
Finn Egil SkjeldestadResearch Group Epidemiology of Chronic Diseases, Institute of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway.
University Hospital of North Norway · NOUiT The Arctic University of Norway · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo assess the performance of a 5-type human papillomavirus (HPV) messenger RNA (mRNA) test in primary screening within the framework of the Norwegian population-based screening programme.

designNationwide register-based cohort study.

settingIn 2003-2004, general practitioners and gynaecologists recruited 18 852 women for participation in a primary screening study with a 5-type HPV mRNA test.

participantsAfter excluding women with a history of abnormal smears and with cervical intraepithelial neoplasia grade 2 (CIN2+) before or until 3 months after screening, 11 220 women aged 25-69 years were eligible for study participation. The Norwegian Cancer Registry completed follow-up of CIN2+ through 31 December 2009.

interventionsFollow-up according to the algorithm for cytology outcomes in the population-based Norwegian Cervical Cancer Screening Programme.

main outcome measuresWe estimated cumulative incidence of CIN grade 3 or worse (CIN3+) 72 months after the 5-type HPV mRNA test.

results3.6% of the women were HPV mRNA-positive at baseline. The overall cumulative rate of CIN3+ was 1.3% (95% CI 1.1% to 1.5%) through 72 months of follow-up, 2.3% for women aged 25-33 years (n=3277) and 0.9% for women aged 34-69 years (n=7943). Cumulative CIN3+ rates by baseline status for HPV mRNA-positive and mRNA-negative women aged 25-33 years were 22.2% (95% CI 14.5% to 29.8%) and 0.9% (95% CI 0.4% to 1.4%), respectively, and 16.6% (95% CI 10.7% to 22.5%) and 0.5% (95% CI 0.4% to 0.7%), respectively, in women aged 34-69 years.

conclusionsThe present cumulative incidence of CIN3+ is similar to rates reported in screening studies via HPV DNA tests. Owing to differences in biological rationale and test characteristics, there is a trade-off between sensitivity and specificity that must be balanced when decisions on HPV tests in primary screening are taken. HPV mRNA testing may be used as primary screening for women aged 25-33 years and 34-69 years.

Indexed as

AdultAgedEarly Detection of CancerFemaleHumansIncidenceMass ScreeningMiddle AgedNorwayPapillomaviridaePapillomavirus InfectionsProspective StudiesRNA, MessengerRNA, ViralSensitivity and SpecificityUterine Cervical DysplasiaRNA, MessengerRNA, Viralcervical cancer screeningcervical intraepithelial neoplasiaCIN3+hpvhpv mrna testhpv primary screening

Identifiers

PMID27515759
PMCPMC4985920
OpenAlexW2516725646

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.